C Trenkwalder

Summary

Country: Germany

Publications

  1. ncbi Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome
    Valerie Voon
    Behavioural and Clinical Neurosciences Institute, University of Cambridge, Cambridge, UK
    BMC Neurol 11:117. 2011
  2. ncbi Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations
    Florian Then Bergh
    Section of Neurology, Max Planck Institut fur Psychiatrie, Munchen, Germany
    BMC Neurol 6:19. 2006
  3. ncbi Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch
    Birgit Hogl
    Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    BMC Neurol 10:86. 2010
  4. ncbi Restless legs syndrome: overdiagnosed or underdiagnosed?
    Claudia Trenkwalder
    Department of Neurology, Ludwig Maximilian University Munich, Germany
    Nat Clin Pract Neurol 3:474-5. 2007
  5. ncbi Augmentation in restless legs syndrome is associated with low ferritin
    Claudia Trenkwalder
    Paracelsus Elena Hospital, Kassel, Germany
    Sleep Med 9:572-4. 2008
  6. ncbi Tireless work on restless legs: guest editors' introduction
    Claudia Trenkwalder
    Paracelsus-Elena Hospital, Center of Parkinsonism and Movement Disorders, Klinikstr. 16, 34128 Kassel, Germany
    Mov Disord 22:S393-4. 2007
  7. ncbi The restless legs syndrome
    Claudia Trenkwalder
    Paracelsus Elena Klinik, Centre of Parkinsonism and Movement Disorders, Kassel, Germany
    Lancet Neurol 4:465-75. 2005
  8. ncbi Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome
    Claudia Trenkwalder
    Paracelsus Elena Klinik, Kassel, Germany
    Mov Disord 21:1404-10. 2006
  9. ncbi Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial
    Claudia Trenkwalder
    Paracelsus Elena Hospital, Kassel, Germany
    Lancet Neurol 7:595-604. 2008
  10. ncbi Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice
    Claudia Trenkwalder
    Paracelsus Elena Hospital, Center of Parkinsonism and Movement Disorders, Kassel, Germany
    Mov Disord 23:2267-302. 2008

Collaborators

Detail Information

Publications107 found, 100 shown here

  1. ncbi Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome
    Valerie Voon
    Behavioural and Clinical Neurosciences Institute, University of Cambridge, Cambridge, UK
    BMC Neurol 11:117. 2011
    ..With this study we sought to assess the cross-sectional prevalence of impulse control behaviours (ICBs) in restless legs syndrome (RLS) and to determine factors associated with ICBs in a population cohort in Germany...
  2. ncbi Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations
    Florian Then Bergh
    Section of Neurology, Max Planck Institut fur Psychiatrie, Munchen, Germany
    BMC Neurol 6:19. 2006
    ..Intermittent IV-MP, alone or with immunomodulators, has been suggested but insufficiently studied as a strategy to prevent relapses...
  3. ncbi Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch
    Birgit Hogl
    Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    BMC Neurol 10:86. 2010
    ..This study reports the 2-year follow-up safety and efficacy data of an ongoing open-label multicenter extension study (NCT00498186) of transdermal rotigotine in patients with moderate to severe restless legs syndrome (RLS)...
  4. ncbi Restless legs syndrome: overdiagnosed or underdiagnosed?
    Claudia Trenkwalder
    Department of Neurology, Ludwig Maximilian University Munich, Germany
    Nat Clin Pract Neurol 3:474-5. 2007
  5. ncbi Augmentation in restless legs syndrome is associated with low ferritin
    Claudia Trenkwalder
    Paracelsus Elena Hospital, Kassel, Germany
    Sleep Med 9:572-4. 2008
    ..We aimed to analyze the relationship between baseline ferritin level and occurrence of augmentation in a retrospective analysis of a prospective double-blind trial of cabergoline versus levodopa on augmentation in RLS...
  6. ncbi Tireless work on restless legs: guest editors' introduction
    Claudia Trenkwalder
    Paracelsus-Elena Hospital, Center of Parkinsonism and Movement Disorders, Klinikstr. 16, 34128 Kassel, Germany
    Mov Disord 22:S393-4. 2007
  7. ncbi The restless legs syndrome
    Claudia Trenkwalder
    Paracelsus Elena Klinik, Centre of Parkinsonism and Movement Disorders, Kassel, Germany
    Lancet Neurol 4:465-75. 2005
    ..Various other drugs, such as opioids, gabapentin, and benzodiazepines, provide alternative treatment possibilities...
  8. ncbi Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome
    Claudia Trenkwalder
    Paracelsus Elena Klinik, Kassel, Germany
    Mov Disord 21:1404-10. 2006
    ..The great majority of adverse events (AEs) were mild or moderate, and of expected types. Augmentation was considered an AE, but in this population of responders it did not occur...
  9. ncbi Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial
    Claudia Trenkwalder
    Paracelsus Elena Hospital, Kassel, Germany
    Lancet Neurol 7:595-604. 2008
    ..Continuous administration of a dopamine agonist could be used to treat patients with restless legs syndrome. Our aim was to investigate the efficacy of transdermal rotigotine in the treatment of idiopathic restless legs syndrome...
  10. ncbi Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice
    Claudia Trenkwalder
    Paracelsus Elena Hospital, Center of Parkinsonism and Movement Disorders, Kassel, Germany
    Mov Disord 23:2267-302. 2008
    ....
  11. ncbi [Intermittent apomorphine injections as rescue therapy for advanced Parkinson's disease. Consensus statement]
    C Trenkwalder
    Zentrum für Parkinson Syndrome und Bewegungsstörungen, Paracelsus Elena Klinik, Klinikstrasse 16, 34128, Kassel, Deutschland
    Nervenarzt 79:475-9. 2008
    ..In the present consensus statement, concepts for the use of apomorphine are presented and discussed based on existing study results, indications, and contraindications. Recommendations for a practical approach are also provided...
  12. ncbi Recent advances in the diagnosis, genetics and treatment of restless legs syndrome
    Claudia Trenkwalder
    Paracelsus Elena Hospital, Center of Parkinsonism and Movement Disorders, Klinikstr 16, 34128, Kassel, Germany
    J Neurol 256:539-53. 2009
    ..An overview on therapeutic options and recent trials is given based on evidence-based management strategies for this common disorder...
  13. ncbi Parkinson's disease sleep scale--validation of the revised version PDSS-2
    Claudia Trenkwalder
    Paracelsus Elena Hospital, Kassel, Germany
    Mov Disord 26:644-52. 2011
    ..The previous Parkinson's disease sleep scale (PDSS) is a 15-item visual analogue scale that assesses the profile of nocturnal disturbances in Parkinson's disease (PD) patients...
  14. ncbi Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial
    Claudia Trenkwalder
    Paracelsus Elena Hospital, University of Gottingen, Kassel, Germany
    Mov Disord 22:696-703. 2007
    ..0001). This first large-scale active controlled study in RLS showed superior efficacy of cabergoline versus levodopa after a 30-week long-term therapy. Tolerability was found more favorable with levodopa than with cabergoline...
  15. ncbi Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER)
    Claudia Trenkwalder
    Department of Clinical Neurophysiology, University of Goettingen and Paracelsus Elena Klinik, Kassel, Germany
    Mov Disord 26:90-9. 2011
    ..Twenty-four-hour transdermal delivery of rotigotine to PD patients with early-morning motor dysfunction resulted in significant benefits in control of both motor function and nocturnal sleep disturbances...
  16. ncbi Clinical trials in restless legs syndrome--recommendations of the European RLS Study Group (EURLSSG)
    Claudia Trenkwalder
    Paracelsus Elena Hospital, Center of Parkinsonism and Movement Disorders, Klinikstr 16, 34128 Kassel, Germany
    Mov Disord 22:S495-504. 2007
    ..The aim of these recommendations is to support research groups or pharmaceutical companies in the design of optimized study protocols...
  17. ncbi The weight of evidence for ropinirole in restless legs syndrome
    C Trenkwalder
    Center for Parkinsonism and Movement Disorders, University of Göttingen and Paracelsus Elena Klinik, Kassel, Germany
    Eur J Neurol 13:21-30. 2006
    ..Furthermore, ropinirole is generally well tolerated. Ropinirole thus represents a potential valuable approach to the management of RLS...
  18. ncbi One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome
    Wolfgang H Oertel
    Department of Neurology, Philipps Universitat, Marburg, Germany
    Sleep Med 9:865-73. 2008
    ..Long-term efficacy and tolerability data are not yet available for patch formulations of dopamine agonists in restless legs syndrome...
  19. ncbi Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe
    Wolfgang H Oertel
    Department of Neurology, Philipps University, Rudolf Bultmann Strasse 8, D 35039 Marburg, Germany
    Sleep Med 9:228-39. 2008
    ..In a pilot placebo-controlled study, low dosages of 0.5-2mg/24h rotigotine showed a dose-dependent beneficial effect in restless legs syndrome (RLS) patients...
  20. ncbi Long-term effects of pergolide in the treatment of restless legs syndrome
    K Stiasny
    Department of Neurology, Center of Nervous Diseases, Philipps University of Marburg, Germany
    Neurology 56:1399-402. 2001
    ..0001). Side effects, in particular nausea, were common but were well controlled by domperidone in most patients...
  21. ncbi Reduced striatal dopaminergic innervation shown by IPT and SPECT in patients under neuroleptic treatment: need for levodopa therapy?
    J Schwarz
    Department of Neurology, Klinikum Grosshadern, Ludwig Maximilians University Munich, Germany
    Psychiatry Res 83:23-8. 1998
    ..Imaging of dopamine transporters with SPECT and IPT or a related compound represents an attractive alternative to the more complex measurements of fluorodopa uptake with positron emission tomography (PET)...
  22. ncbi Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries
    C Trenkwalder
    Department of Clinical Neurophysiology, Paracelsus Elena Klinik, University of Gottingen, Gottingen, Germany
    J Neurol Neurosurg Psychiatry 75:92-7. 2004
    ..To assess the efficacy, safety, and tolerability of ropinirole in the treatment of patients with restless legs syndrome...
  23. ncbi L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial
    C Trenkwalder
    Department of Neurology, University of Munich, Klinikum Grosshadern, Germany
    Sleep 18:681-8. 1995
    ..030) while the patients received L-dopa therapy. We conclude that L-dopa 100-200 mg proved to be effective in idiopathic RLS and for the first time under controlled conditions in uremic RLS without any severe side effects...
  24. ncbi Striatal dopamine transporter binding assessed by [I-123]IPT and single photon emission computed tomography in patients with early Parkinson's disease: implications for a preclinical diagnosis
    J Schwarz
    Department of Neurology, University of Ulm, Germany
    Arch Neurol 57:205-8. 2000
    ..Specific binding to dopamine transporters may serve as a tool to detect early loss of nigrostriatal dopaminergic neurons in patients with Parkinson's disease...
  25. ncbi Normal IPT and IBZM SPECT in drug-naive and levodopa-treated idiopathic restless legs syndrome
    I Eisensehr
    Department of Neurology, Ludwig Maximilians University, Munich, Germany
    Neurology 57:1307-9. 2001
    ..The authors conclude that striatal dopamine transporter and receptor density is normal in drug-naive and levodopa-treated patients with RLS...
  26. ncbi Improvement of motor fluctuations in patients with Parkinson's disease following treatment with high doses of pergolide and cessation of levodopa
    J Schwarz
    Department of Neurology, Klinikum Grosshadern, Ludwig Maximilians University, Munich, Germany
    Eur Neurol 37:236-8. 1997
    ..These data show that in some patients oral treatment with high doses of a dopamine agonist may improve the severity of motor fluctuations and achieve a good control of parkinsonian signs without concomitant levodopa treatment...
  27. ncbi Growth hormone response in low-dose apomorphine test correlates with nigrostriatal dopamine transporter binding in patients with Parkinson's disease
    S Happe
    Department of Clinical Neurophysiology, University of Gottingen, Gottingen, Germany
    J Neural Transm 114:589-94. 2007
    ..490 and -0.587; p between 0.04 and 0.01). Challenge with low-dose apomorphine may therefore be used as an indirect tool to measure the extent of nigrostriatal neurodegeneration in early PD...
  28. ncbi Efficacy of pergolide in treatment of restless legs syndrome: the PEARLS Study
    C Trenkwalder
    Department of Clinical Neurophysiology, Georg August University, Goettingen, Germany
    Neurology 62:1391-7. 2004
    ..To evaluate the short- and long-term safety and efficacy of pergolide therapy for restless legs syndrome (RLS) in a double-blind, placebo-controlled, randomized trial (Pergolide European Australian RLS [PEARLS] study)...
  29. ncbi Dopaminergic treatment is associated with decreased body weight in patients with Parkinson's disease and dyskinesias
    C G Bachmann
    Department of Clinical Neurophysiology, Georg August University, Gottingen, Germany
    Eur J Neurol 16:895-901. 2009
    ..We aimed to investigate whether PD patients with dyskinesias display body weight alterations and to observe any correlations between medication and other putative determinants...
  30. ncbi Restless legs syndrome--new insights into clinical characteristics, pathophysiology, and treatment options
    K Stiasny-Kolster
    Department of Neurology, Philipps University Marburg, Rudolf Bultmann Strasse 8, 35033 Marburg, Germany
    J Neurol 251:VI/39-43. 2004
    ..Placebo-controlled large-scale phase II and III treatment trials have shown that dopamine agonists are safe and efficacious agents for the treatment of this disorder...
  31. ncbi RLS3: fine-mapping of an autosomal dominant locus in a family with intrafamilial heterogeneity
    K M Liebetanz
    Department of Clinical Neurophysiology, Georg-August-University, Goettingen, Germany
    Neurology 67:320-1. 2006
    ..P values were 0.0054 for marker D9S1810 for TDT and 0.0009 for the affecteds-only linkage analysis, providing a confirmation of RLS3. This study narrows the region containing the autosomal dominant RLS3 locus to 11.1 cM (16.6 Mbp)...
  32. ncbi Circadian variation in restless legs syndrome
    P C Baier
    Department of Clinical Neurophysiology, Georg August University of Gottingen, Gottingen, Germany
    Sleep Med 8:645-50. 2007
    ..This contribution reviews the current literature on circadian variation in RLS and discusses potential intrinsic and extrinsic causes...
  33. ncbi Movement disorders in sleep: Parkinson's disease and restless legs syndrome
    S Happe
    Department of Clinical Neurophysiology, University of Gottingen, Germany
    Biomed Tech (Berl) 48:62-7. 2003
    ..The present review focuses on nocturnal motor activity and sleep in Parkinson's disease and RLS...
  34. ncbi Substantia nigra echogenicity in progressive supranuclear palsy
    Jens Ebentheuer
    Paracelsus Elena Klinik, Center of Parkinsonism and Movement Disorders, Kassel, Germany
    Mov Disord 25:773-7. 2010
    ..1 +/- 2.43). In RS patients a normoechogenic SN (26 of 27) and an enlarged third ventricle (mean mm) +/-SD: 10.3 +/- 2.41) was found. These differences may elucidate the pathological differences of RS and PSP-P...
  35. ncbi Rotigotine transdermal delivery for the treatment of restless legs syndrome
    Friederike Sixel-Döring
    Center of Parkinsonism and Movement Disorders, Paracelsus Elena Hospital, Klinikstrasse 16, 34128 Kassel, Germany
    Expert Opin Pharmacother 11:649-56. 2010
    ..Constant drug delivery and ease of use due to the application of an adhesive patch once daily are the potential advantages of the rotigotine patch for the treatment of RLS...
  36. ncbi Validation of the "L-DOPA test" for diagnosis of restless legs syndrome
    Karin Stiasny-Kolster
    Department of Neurology, Center of Nervous Diseases, Philipps University, Marburg, Germany
    Mov Disord 21:1333-9. 2006
    ..We recommend the L-DOPA test for diagnostic decision making in all patients with an unclear RLS diagnosis according to the essential diagnostic criteria of the International RLS Study Group...
  37. ncbi The role of opioids in restless legs syndrome: an [11C]diprenorphine PET study
    Sarah von Spiczak
    Division of Neuroscience and MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College, London, UK
    Brain 128:906-17. 2005
    ..We therefore discuss a possible role for opioids in the pathophysiology of RLS with respect to sensory and motor symptoms...
  38. ncbi Differentiation of typical and atypical Parkinson syndromes by quantitative MR imaging
    N K Focke
    Department of Clinical Neurophysiology, Georg August University Gottingen, Gottingen, Germany
    AJNR Am J Neuroradiol 32:2087-92. 2011
    ..We, therefore, conducted a head-to-head study with different quantitative MR imaging measurements in patients with IPS, MSA-type Parkinson, PSP, and healthy elderly controls...
  39. ncbi The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease
    K R Chaudhuri
    Department of Neurology, King s College Hospital, London SE5, UK
    J Neurol Neurosurg Psychiatry 73:629-35. 2002
    ..No formal instruments are available for quantifying sleep problems in Parkinson's disease...
  40. ncbi Clinical symptomatology and treatment of restless legs syndrome and periodic limb movement disorder
    Karin Stiasny
    Department of Neurology, Center of Nervous Diseases, Philipps University of Marburg, Germany
    Sleep Med Rev 6:253-65. 2002
    ..This article gives an overview of the epidemiology, pathophysiology, clinical symptomatology and diagnosis of RLS and PLMD and focuses on treatment strategies in both disorders...
  41. ncbi Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome
    Walter Paulus
    Department of Clinical Neurophysiology, University of Gottingen, Gottingen, Germany
    Lancet Neurol 5:878-86. 2006
    ....
  42. ncbi Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease
    Svenja Happe
    Department of Clinical Neurophysiology, University of Gottingen, Germany
    Mov Disord 19:1511-5. 2004
    ..Thus, the low-dose apomorphine test may also be a useful biological marker in the early differential diagnosis of PD patients who have already received levodopa treatment...
  43. ncbi Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial)
    Richard Dodel
    Department of Neurology, Philipps University of Marburg, 35039 Marburg, Germany
    Mov Disord 25:97-107. 2010
    ..This prospective, 48 week, randomized, double-blind, multinational study failed to show a clinical effect of minocycline on symptom severity as assessed by clinical motor function...
  44. ncbi [Diagnosis and clinical therapy for Parkinson's disease]
    S Wenzel
    Paracelsus Elena Klinik, Klinikstrasse 16, 34128 Kassel, Germany
    Nervenarzt 77:1439-43. 2006
    ..The difficulties and related problems affect prognosis more than do the motor symptoms. There is a need for standardized diagnostic and specific therapeutic intervention, but appropriate studies are still lacking...
  45. ncbi Combined treatment with corticosteroids and moclobemide favors normalization of hypothalamo-pituitary-adrenal axis dysregulation in relapsing-remitting multiple sclerosis: a randomized, double blind trial
    F Then Bergh
    Department of Neurology, Max Planck Institute of Psychiatry, 80804 Munich, Germany
    J Clin Endocrinol Metab 86:1610-5. 2001
    ..Although corticosteroids alone had no effect on the HPA response using the dexamethasone-CRH test, treatment with moclobemide combined with corticosteroids favors normalization of the HPA response in relapsing-remitting MS...
  46. ncbi Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters
    P Flachenecker
    Department of Neurology, Julius Maximilians Universitat Wurzburg, Wurzburg, Germany
    Mult Scler 8:523-6. 2002
    ..Secondly, to further clarify the nature of fatigue, we investigated its relation to physical disability, course of the disease, immunotherapy, and depression...
  47. ncbi Imaging of nonmotor symptoms in Parkinson syndromes
    W Paulus
    Department of Clinical Neurophysiology, University Hospital, Gottingen, Germany
    Clin Neurosci 5:115-20. 1998
    ..To investigate the pathophysiology of hallucinations with functional imaging may be a promising field of future research...
  48. ncbi Deep brain stimulation for the treatment of Parkinson's disease: subthalamic nucleus versus globus pallidus internus
    M Krause
    Department of Neurology, University of Heidelberg, INF 400, 69120 Heidelberg, Germany
    J Neurol Neurosurg Psychiatry 70:464-70. 2001
    ..The aim of this prospective study is to compare the long term effects of GPi and STN stimulation in patients with severe Parkinson's disease...
  49. ncbi Polysomnographic findings, video-based sleep analysis and sleep perception in progressive supranuclear palsy
    Friederike Sixel-Döring
    Paracelsus Elena Hospital, Center of Parkinsonism and Movement Disorders, Klinikstr 16, 34128 Kassel, Germany
    Sleep Med 10:407-15. 2009
    ....
  50. ncbi Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing
    Jan Schindehütte
    Paracelsus Elena Klinik Kassel, Klinikstrasse 16, 34128 Kassel, Germany
    Clin Neurol Neurosurg 109:188-91. 2007
    ..Ziprasidone may serve as an additional "atypical anti-psychotic" for the treatment of DP in PD but can also induce deterioration of motor function...
  51. ncbi Growth hormone response to low-dose apomorphine in restless legs syndrome
    Svenja Happe
    Department of Clinical Neurophysiology, University of Gottingen, Germany
    Growth Horm IGF Res 17:323-7. 2007
    ..It is therefore the aim of this study to determine whether the GH response to subcutaneously applied low-dose apomorphine is generally altered in patients with RLS as compared to healthy controls...
  52. ncbi Affective and cognitive Theory of Mind in patients with parkinson's disease
    Maren E Bodden
    Department of Neurology, Philipps University Marburg, Marburg, Germany
    Parkinsonism Relat Disord 16:466-70. 2010
    ....
  53. ncbi Restless legs syndrome: pathophysiology, clinical presentation and management
    Claudia Trenkwalder
    Paracelsus Elena Hospital, Center of Parkinsonism and Movement Disorders, Klinikstrasse 16, 34128 Kassel, Germany
    Nat Rev Neurol 6:337-46. 2010
    ..Here, we review the latest studies pertaining to the pathophysiology, clinical presentation and management of RLS...
  54. ncbi Assessing health-related quality of life in patients with restless legs syndrome
    Svenja Happe
    Department of Clinical Neurophysiology, Klinikum Bremen Ost, Bremen, Germany
    Sleep Med 10:295-305. 2009
    ..Restless Legs Syndrome (RLS) has a substantial impact on normal daily activities. Because of the high prevalence it is necessary to evaluate the impact on the health-related quality of life (HRQoL)...
  55. ncbi Retention of dopamine 2 receptor mRNA and absence of the protein in craniospinal and extracranial metastasis of a malignant prolactinoma: a case report
    J Winkelmann
    Department of Neurology, Max Planck Institute of Psychiatry, Kraepelinstrasse 10, 80804 Munich, Germany
    Eur J Endocrinol 146:81-8. 2002
    ..In this case, the presence of dopamine 2 receptor (D2R) was studied at the mRNA and protein level, in order to understand the pathological background of the resistance to treatment with different dopamine agonists...
  56. ncbi Why do restless legs occur at rest?--pathophysiology of neuronal structures in RLS. Neurophysiology of RLS (part 2)
    C Trenkwalder
    Department of Clinical Neurophysiology, University of Gottingen, Gottingen, Germany
    Clin Neurophysiol 115:1975-88. 2004
    ..A diversity of hypothetical affections of different neuronal levels might lead to various combinations of RLS symptomatology. No single pathophysiological explanation has yet been developed that covers all clinical features...
  57. ncbi Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer's disease
    B Mollenhauer
    Department of Neurology, Georg August University, Goettingen, Germany
    J Neural Transm 112:933-48. 2005
    ..Follow-up CSF analyses are of limited value for the differentiation of AD and DLB. We conclude that more specific markers have to be established for the differentiation and follow-up of these diseases...
  58. ncbi State of the art in restless legs syndrome therapy: practice recommendations for treating restless legs syndrome
    Wolfgang H Oertel
    Department of Neurology, Philipps University, Marburg, Germany
    Mov Disord 22:S466-75. 2007
    ..Opioids and anticonvulsants such as gabapentine are second-line options in individual patients. Iron substitution is justified in people with iron deficiency related RLS (ferritin concentration lower than 50 microg/L)...
  59. ncbi High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias
    Alexander Storch
    Department of Neurology, University of Ulm, Ulm, Germany
    Parkinsonism Relat Disord 11:393-8. 2005
    ..Controlled trials are needed to further substantiate the efficacy and safety of this treatment strategy...
  60. ncbi Impact of regular LDL apheresis on the development of restless legs syndrome
    Tobias Tings
    Department of Clinical Neurophysiology, University of Goettingen, Robert Koch Str 40, 37075 Goettingen, Germany
    Mov Disord 19:1072-5. 2004
    ..Substitution of iron therefore may be a promising line of treatment for LA-induced RLS...
  61. ncbi Role of dopamine receptor agonists in the treatment of restless legs syndrome
    Svenja Happe
    Department of Clinical Neurophysiology, University of Gottingen, Gottingen, Germany
    CNS Drugs 18:27-36. 2004
    ..Further research should focus on long-term observations and comparisons of different dopamine receptor agonists in RLS...
  62. ncbi Training effects outweigh effects of single-session conventional rTMS and theta burst stimulation in PD patients
    Holger Rothkegel
    Department of Clinical Neurophysiology, University of Gottingen, Gottingen, Germany
    Neurorehabil Neural Repair 23:373-81. 2009
    ..Focal single-session repetitive transcranial magnetic stimulation (rTMS) of the primary motor cortex has been claimed to be capable of improving motor function in Parkinson's disease...
  63. ncbi Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study
    Karla Eggert
    German Competence Network on Parkinson s Disease, Department of Neurology, Philipps University Marburg, Marburg, Germany
    Mov Disord 25:896-905. 2010
    ..Adverse events were similar across treatment groups. Perampanel treatment was well tolerated and safe, but failed to achieve statistical significance in primary and secondary endpoints...
  64. ncbi Pathophysiological concepts of restless legs syndrome
    Walter Paulus
    Department of Clinical Neurophysiology, University of Gottingen, Gottingen, Germany
    Mov Disord 22:1451-6. 2007
    ..Neurophysiologically excitability alterations can be measured by a variety of methods such as determination of pain thresholds, H-reflex testing, and quantitative sensory testing...
  65. ncbi Skin complications in deep brain stimulation for Parkinson's disease: frequency, time course, and risk factors
    Friederike Sixel-Döring
    Paracelsus Elena Klinik, Center of Parkinsonism and Movement Disorders, Klinikstr 16, 34128 Kassel, Germany
    Acta Neurochir (Wien) 152:195-200. 2010
    ....
  66. ncbi Update of the pathophysiology of the restless-legs-syndrome
    Walter Paulus
    Department of Clinical Neurophysiology, University of Gottingen, Gottingen, Germany
    Mov Disord 22:S431-9. 2007
    ..Furthermore, this may create a framework to help understand why dopamine, opioid, and some anticonvulsant therapies are effective in RLS patients...
  67. ncbi T2*-weighted MRI in diagnosis of multiple system atrophy. A practical approach for clinicians
    Friederike von Lewinski
    Paracelsus Elena Klinik, Klinikstr 16, 34128 Kassel, Germany
    J Neurol 254:1184-8. 2007
    ..T2*-weighted magnetic resonance imaging (MRI) gradient echo (GE) sequences are sensitive for paramagnetic susceptibility changes and therefore may support the clinical differential diagnosis between MSA and PD...
  68. ncbi Neurochemical biomarkers in the differential diagnosis of movement disorders
    Brit Mollenhauer
    Paracelsus Elena Klinik, Kassel, Germany
    Mov Disord 24:1411-26. 2009
    ..In this article, we review CSF biomarkers in these movement disorders and discuss recent published reports on the neurochemical intra vitam diagnosis of neurodegenerative disorders (including recent CSF alpha-synuclein findings)...
  69. ncbi Dyskinesias due to intravenous apomorphine abuse in a patient without basal ganglia disorder
    Svenja Happe
    Department of Clinical Neurophysiology, University of Gottingen, Germany
    Mov Disord 20:105-8. 2005
    ..We describe a patient with psychogenic parkinsonism and intravenous apomorphine abuse leading to subsequent choreatiform dyskinesias...
  70. ncbi Circadian distribution of motor-activity in unilaterally 6-hydroxy-dopamine lesioned rats
    Paul Christian Baier
    Department of Clinical Neurophysiology, Georg August University Gottingen, Robert Koch Str 40, 37075, Gottingen, Germany
    Exp Brain Res 169:283-8. 2006
    ..In order to further elucidate the described phenomena, it will be necessary to perform studies combining sleep recordings with locomotor activity measurements...
  71. ncbi Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies
    Brit Mollenhauer
    Department of Neurology, Georg August University Gottingen, Gottingen, Germany
    Dement Geriatr Cogn Disord 19:164-70. 2005
    ..We conclude that more specific markers have to be established for the differentiation of these diseases...
  72. ncbi Restless-legs syndrome in primary care: counting patients in Idaho
    Claudia Trenkwalder
    Department of Clinical Neurophysiology, University of Goettingen, Paracelsus-Elena Klinik, Klinikstr. 16, D-34128 Kassel, Germany
    Lancet Neurol 3:83. 2004
  73. ncbi Restless legs syndrome and periodic limb movements
    Claudia Trenkwalder
    Department of Clinical Neurophysiology, University of Goettingen, Goettingen, Germany
    Adv Neurol 89:145-51. 2002
  74. ncbi Increased muscle activity during rapid eye movement sleep correlates with decrease of striatal presynaptic dopamine transporters. IPT and IBZM SPECT imaging in subclinical and clinically manifest idiopathic REM sleep behavior disorder, Parkinson's disease
    Ilonka Eisensehr
    Department of Neurology, University of Munich, Germany
    Sleep 26:507-12. 2003
    ....
  75. ncbi One-year treatment with standard and sustained-release levodopa: appropriate long-term treatment of restless legs syndrome?
    Claudia Trenkwalder
    Max Planck Institute of Psychiatry, Munich, Germany
    Mov Disord 18:1184-9. 2003
    ....
  76. ncbi Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome
    Arthur S Walters
    New Jersey Neuroscience Institute, JFK Medical Center, Edison, NJ 08818, USA
    Sleep Med 4:121-32. 2003
    ..Moreover, RLS is primarily a subjective disorder. Therefore, a subjective scale is at present the optimal instrument to meet this need...
  77. ncbi Microstructure of the non-rapid eye movement sleep electroencephalogram in patients with newly diagnosed Parkinson's disease: effects of dopaminergic treatment
    Hans Brunner
    Max Planck Institute of Psychiatry, Munich, Germany
    Mov Disord 17:928-33. 2002
    ..It is suggested that Parkinson's disease as well as the application of dopaminergic drugs exerts a desynchronizing effect on the sleep EEG that is reflected in a disruption of sleep continuity...
  78. ncbi Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute
    Diego Garcia-Borreguero
    Sleep Research Institute, Alberto Alcocer 19, 28036 Madrid, Spain
    Sleep Med 8:520-30. 2007
    ..The Consensus Conference sought to develop a better understanding of augmentation and generate a better operational definition for its clinical identification...
  79. ncbi Validation of the Augmentation Severity Rating Scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndrome
    Diego Garcia-Borreguero
    Fundacion Jimenez Diaz, Madrid, Spain
    Sleep Med 8:455-63. 2007
    ..The changes in each dimension are summed to give an ASRS total score...
  80. ncbi Relationship of periodic leg movements and severity of restless legs syndrome: a study in unmedicated and medicated patients
    Magdolna Hornyak
    Department of Psychiatry and Psychotherapy, University Medical Center, Freiburg, Germany
    Clin Neurophysiol 118:1532-7. 2007
    ....
  81. ncbi Mapping the effects of three dopamine agonists with different dyskinetogenic potential and receptor selectivity using pharmacological functional magnetic resonance imaging
    Marina Delfino
    Laboratorio de Parkinsonismo Experimental, Instituto de Investigaciones Farmacologicas, CONICET, Buenos Aires, Argentina
    Neuropsychopharmacology 32:1911-21. 2007
    ..Our results suggest that striatal and cortical activation induced by stimulation of D1/D5 receptors has a primary role in the induction of peak dose dyskinesia in parkinsonism...
  82. ncbi Presynaptic dopaminergic function in patients with restless legs syndrome: are there common features with early Parkinson's disease?
    Rainer Linke
    Department of Nuclear Medicine, University of Munich, Munich, Germany
    Mov Disord 19:1158-62. 2004
    ..Our results do not strengthen an identical pathophysiologic pathway between RLS and PD on the level of nigrostriatal presynaptic terminal function...
  83. ncbi Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health
    Richard P Allen
    Department of Neurology, Sleep Medicine, Johns Hopkins Bayview Medical Center, Asthma and Allergy Building 1B46b, 5501 Hopkins Bayview Circle, Baltimore, MD 21224, USA
    Sleep Med 4:101-19. 2003
    ..Modification of the criteria is now necessary to better reflect that increased body of knowledge, as well as to clarify slight confusion with the wording of the original criteria...
  84. ncbi Iron metabolism and the risk of restless legs syndrome in an elderly general population--the MEMO-Study
    Klaus Berger
    Institute of Epidemiology and Social Medicine, University of Muenster, Domagkstr 3, 48149 Muenster, Germany
    J Neurol 249:1195-9. 2002
    ..All reports are based on single cases or case series of hospitalized patients or those from outpatient clinics. No data from population studies are available...
  85. ncbi Point mutations in exon 1 of the NR4A2 gene are not a major cause of familial Parkinson's disease
    Alexander Zimprich
    Neurogenetics 4:219-20. 2003
  86. ncbi Restless Legs Syndrome induced by impairment of sensory spinal pathways
    Tobias Tings
    J Neurol 250:499-500. 2003
  87. ncbi T2*-weighted MRI differentiates multiple system atrophy from Parkinson's disease
    Eduard Kraft
    Max Planck Institute of Psychiatry, Munich, Germany
    Neurology 59:1265-7. 2002
    ..Hypointense putaminal signal changes were more often observed in MSA than in PD using T2* but not T2-weighted images, indicating that T2*-weighted GE sequences are of diagnostic value for patients with parkinsonism...
  88. ncbi Long-term course of restless legs syndrome in dialysis patients after kidney transplantation
    Juliane Winkelmann
    Max Planck Institute of Psychiatry, Munich, Germany
    Mov Disord 17:1072-6. 2002
    ..Kidney transplantation has a strong and positive influence on RLS symptoms in hemodialysis patients. Hemodialysis patients can expect a substantial improvement of RLS symptoms after a successful kidney transplant...
  89. ncbi Complex segregation analysis of restless legs syndrome provides evidence for an autosomal dominant mode of inheritance in early age at onset families
    Juliane Winkelmann
    Section of Neurology, Max Planck Institute of Psychiatry, Munich, Germany
    Ann Neurol 52:297-302. 2002
    ..The segregation pattern found in our families argues for an autosomal allele acting dominantly in RLS families with an early age at onset of symptoms and suggests that RLS is a causative heterogeneous disease...
  90. ncbi Assessment of spontaneously occurring periodic limb movements in sleep in the rat
    Paul Christian Baier
    Sleep Pharmacology, Max Planck Institute of Psychiatry, Kraepelinstr 2 10, 80804 Munich, Germany
    J Neurol Sci 198:71-7. 2002
    ..The objective of this study is to explore whether a PLMS-like phenomenon can be observed in rodents in order to elucidate the underlying mechanisms...
  91. ncbi The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval
    Alexander Zimprich
    Hertie Institute for Clinical Brain Research, Department for Neurodegenerative Diseases, University of Tuebingen, Tuebingen, Germany
    Am J Hum Genet 74:11-9. 2004
    ..7 Mb). Our data provide evidence that the PARK8 locus is responsible for the disease in a subset of families of white ancestry with autosomal dominant parkinsonism, suggesting that it could be a more common locus...
  92. ncbi Sex and the risk of restless legs syndrome in the general population
    Klaus Berger
    Institute of Epidemiology and Social Medicine, University of Munster, Germany
    Arch Intern Med 164:196-202. 2004
    ..Population-based studies are rare, and risk factors in the general population are not known...
  93. ncbi Family-based association study of the restless legs syndrome loci 2 and 3 in a European population
    David Kemlink
    Institute of Human Genetics, GSF National Research Center for Environment and Health, Munich, Germany
    Mov Disord 22:207-12. 2007
    ..0077, respectively). These results represent the first confirmation of these loci in a mixed European population. Variable results observed in families of different ethnic groups further corroborate the genetic complexity of RLS...
  94. ncbi Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia
    Brit Mollenhauer
    Department of Neurology, Georg August University, Kassel, Germany
    Dement Geriatr Cogn Disord 22:200-8. 2006
    ..These findings suggest that such protein CSF changes may help to support the clinical diagnosis of cognitive decline in PD and that there may be apolipoprotein-E-isoform-specific differences in CSF protein regulation in advanced PDD...
  95. ncbi [Can relaxation exercises calm the legs?]
    Claudia Trenkwalder
    MMW Fortschr Med 148:16. 2006
  96. ncbi Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies
    Brit Mollenhauer
    Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Institutes of Medicine, 77 Avenue Louis Pasteur, Boston, MA 02115, USA
    Neurodegener Dis 4:366-75. 2007
    ..Heart-type fatty acid-binding protein (H-FABP) was recently discovered in CSF and serum of patients with neurodegenerative diseases...
  97. ncbi Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions
    Juliane Winkelmann
    Institute of Human Genetics, GSF National Research Center of Environment and Health, D 85764 Neuherberg, Munich, Germany
    Nat Genet 39:1000-6. 2007
    ..MEIS1 has been implicated in limb development, raising the possibility that RLS has components of a developmental disorder...
  98. ncbi Blood-based neurochemical diagnosis of vascular dementia: a pilot study
    Mirko Bibl
    Department of Psychiatry University of Goettingen, von Siebold Str, Goettingen, Germany
    J Neurochem 103:467-74. 2007
    ..From the presented results, we consider the ratio of plasma Abeta1-38/Abeta1-40 peptides to be a blood-based biomarker candidate for VAD...
  99. ncbi CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia
    Mirko Bibl
    Department of Psychiatry, University of Goettingen, Goettingen, Germany
    Brain 129:1177-87. 2006
    ..Their distinct molecular phenotypes support the view of different pathophysiological pathways for each of these neurodegenerative diseases...
  100. ncbi Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies
    Brit Mollenhauer
    Center for Neurologic Diseases, Department of Neurology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Clin Chem Lab Med 44:192-5. 2006
    ..We conclude that more specific markers have to be established to differentiate between these diseases...